This has actually been beautifully explained by Aditya Khemka sir in his 1.5 hour YouTube video :
Pharma is not 1 market : it is 4000 different molecules and markets. In some markets we are beginning b
to see china+1 play out. In some we have not.
Pharma is not 1 market : it is 4000 different molecules and markets. In some markets we are beginning b
to see china+1 play out. In some we have not.
https://twitter.com/abhymurarka/status/1413535741682929667
In some, india has a cost competitive advantage and so we are able to take market share away from China.
In some we simply cannot compete with China and so china will gain market share.
In some we simply cannot compete with China and so china will gain market share.
As an example : laurus is not seeing any china+1 play out.
The more structural change to track is dependence on china for KSM is going down across the board.
Indian api makers are truly becoming attmanirbhar (or at least reducing china nirbharta).
The more structural change to track is dependence on china for KSM is going down across the board.
Indian api makers are truly becoming attmanirbhar (or at least reducing china nirbharta).
Neuland, Divi's many others are reporting reduction in depenence on China through backward integration and better supply chain management.
At same time, this is capitalism. China won't go down without a fight. Others like Solara see fierce competition from China too:
At same time, this is capitalism. China won't go down without a fight. Others like Solara see fierce competition from China too:
• • •
Missing some Tweet in this thread? You can try to
force a refresh
